Oct 29, 4:11 PM ET
Stryker Corporation announced its third quarter 2026 operating results, reporting a 7.7% increase in net sales to $6.5 billion alongside a decline in reported net earnings. The company updated its full year 2026 guidance, now expecting organic net sales growth in the range of 6.5% to 7.0%. Additionally, the Board of Directors approved a $3.0 billion increase to the share repurchase program following $1.0 billion in repurchases during the quarter.
- Reported net sales increased 7.7% to $6.5 billion for the third quarter of 2026.
- Reported net earnings decreased 12.3% to $753 million, or $1.96 per diluted share, while adjusted diluted EPS increased 10.3% to $3.52.
- Full year 2026 organic net sales growth is now expected to be in the range of 6.5% to 7.0%.
- Stryker repurchased $1.0 billion of its common stock in the third quarter of 2026 and expanded its share repurchase program by $3.0 billion in October 2026.
Read the filing on SEC.gov ↗
Oct 6, 8:08 AM ET
Stryker said CEO Kevin Lobo will step down on December 31, 2026, and become Executive Chair of the Board on January 1, 2027. President and COO Spencer Stiles will become CEO on the same date and join the Board, which the company is expanding from 10 to 11 members. The filing describes this as a planned succession process and does not report any change to financial results or guidance.
- Kevin Lobo resigns as CEO on December 31, 2026, and becomes Executive Chair effective January 1, 2027
- Spencer Stiles, President and COO since January 2026, becomes CEO and a Board member effective January 1, 2027
- Stiles's base salary rises to $1,320,000 and his annual bonus target to 150% of salary; a February 2027 equity award with a target grant value of $14,200,000 will be recommended to independent directors
- Lobo's base salary, bonus target and benefit eligibility are unchanged, but he will not receive new stock awards as Executive Chair
Read the filing on SEC.gov ↗
Jul 30, 4:09 PM ET
Stryker reported second quarter 2026 net sales of $6.6 billion, up 9.4% from a year earlier, with reported diluted EPS of $3.30 and adjusted diluted EPS of $3.69. The company narrowed its full year 2026 guidance to organic net sales growth of 8.3% to 9.3% and adjusted diluted EPS of $14.95 to $15.10, and its CEO said the company is recovering from the cyber incident first reported on March 11, 2026.
- Net sales $6.6 billion, up 9.4% (organic up 9.0%); MedSurg and Neurotechnology $3.6 billion, Orthopaedics $3.0 billion
- Reported diluted EPS $3.30, up 44.1%; adjusted diluted EPS $3.69, up 17.9%
- 2026 guidance narrowed: organic net sales growth 8.3% to 9.3%; adjusted diluted EPS $14.95 to $15.10
Read the filing on SEC.gov ↗
Jun 26, 3:45 PM ET
Stryker filed an 8-K to recast its consolidated financial statements for the three years ended December 31, 2025, to reflect a reorganization that created the Ortho Tech business. The company states that the recast is not a restatement and does not amend its audited financial statements. The company will continue to report two segments, MedSurg and Neurotechnology, and Orthopaedics.
- Ortho Tech combines orthopaedic instruments from the Instruments business with Mako and enabling technologies from Other Orthopaedics.
- Ortho Tech 2025 net sales were $2,770 million, up 11.8% as reported.
- The filing covers 2023, 2024 and 2025, with the recast presented in Exhibit 99.1.
- The filing does not update MD&A; more current information is in the Form 10-Q for the quarter ended March 31, 2026.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.